Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.012
Sell
RSI(14)
29.591
Sell
STOCH(KDJ)(9,3,3)
9.338
Oversold
ATR(14)
0.027
Low Volatility
CCI(14)
-130.026
Sell
Williams %R
94.590
Oversold
TRIX(12,20)
-0.969
Sell
StochRSI(14)
0.000
Oversold
Azitra Inc
AZTR0.208USD
-0.002-0.72%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
1.17MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Azitra Inc
Currency: USD Updated: 2026-02-06Key Insights
Azitra Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 189 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 2.70.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Azitra Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Azitra Inc Highlights
StrengthsRisks
Azitra, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing advanced therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. It has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. Its lead product, ATR-12, is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its advanced product, ATR-04, is a genetically modified strain of S. epidermidis for treating papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, a chronic, xerotic (abnormally dry), and scaly skin disease.
Growing
The company is in a growing phase, with the latest annual income totaling USD 7.50K.
Fairly Valued
The company’s latest PE is -0.16, at a medium 3-year percentile range.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
2.700
Target Price
+1188.78%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of Azitra Inc is 6.81, ranking 208 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.59
Operational Efficiency
2.69
Growth Potential
6.75
Shareholder Returns
7.03
Azitra Inc's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of Azitra Inc is 7.98, ranking 70 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.16, which is -100.49% below the recent high of 0.00 and -81249.04% above the recent low of -131.70.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 189/392
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of Azitra Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 2.70, with a high of 3.40 and a low of 2.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
2.700
Target Price
+1188.78%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
542
Total
6
Median
6
Average
Company name
Ratings
Analysts
Azitra Inc
AZTR
1
CRISPR Therapeutics AG
CRSP
29
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Beigene Ltd
ONC
24
Intellia Therapeutics Inc
NTLA
24
1
2
3
...
109
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of Azitra Inc is 1.82, ranking 383 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.31 and the support level at 0.15, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
0.225
Sell
MA10
0.247
Sell
MA20
0.272
Sell
MA50
0.302
Sell
MA100
0.444
Sell
MA200
0.980
Sell
Institutional Confidence
Currency: USD Updated: 2026-02-06The current institutional shareholding score of Azitra Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 3.33%, representing a quarter-over-quarter decrease of 67.18%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Azitra Inc is 1.40, ranking 319 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
--
VaR
--
240-Day Maximum Drawdown
+89.59%
240-Day Volatility
+241.23%
Return
Best Daily Return
60 days
+24.86%
120 days
+35.88%
5 years
--
Worst Daily Return
60 days
-14.64%
120 days
-18.87%
5 years
--
Sharpe Ratio
60 days
-2.51
120 days
-2.41
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+89.59%
3 years
--
5 years
--
Return-to-Drawdown Ratio
240 days
-0.46
3 years
--
5 years
--
Skewness
240 days
+1.38
3 years
--
5 years
--
Volatility
Realised Volatility
240 days
+241.23%
5 years
--
Standardised True Range
240 days
+36.15%
5 years
--
Downside Risk-Adjusted Return
120 days
-430.52%
240 days
-430.52%
Maximum Daily Upside Volatility
60 days
+82.51%
Maximum Daily Downside Volatility
60 days
+62.83%
Liquidity
Average Turnover Rate
60 days
+33.56%
120 days
+22.96%
5 years
--
Turnover Deviation
20 days
-100.00%
60 days
-100.00%
120 days
-100.00%
Peer Comparison
Biotechnology & Medical Research
Azitra Inc
AZTR
5.30 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ionis Pharmaceuticals Inc
IONS
8.38 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.17 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
